SA PRO
Free Account
Monte Rosa Therapeutics, Inc.GLUENASDAQ
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 88% recommend buying.

Consensus Rating
Buy
8 analysts·Limited coverage
88%
Rating Distribution
Strong Buy
00%
Buy
788%
Hold
113%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 52% higher.

Bear Case
$22.00
+5%
Consensus
$31.75
+52%
Bull Case
$37.00
+77%
Price Range8 analysts
Low
Consensus
High
$22.00
$37.00
Current Target
Current Price
$20.93
Upside to Target
$10.82

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 14, 2026Piper Sandler
Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler
Target:$37.00
+54.2%from $23.99
Jan 7, 2026Jefferies
Monte Rosa Therapeutics price target raised to $31 from $22 at Jefferies
Target:$31.00
+33.1%from $23.29
Jan 7, 2026Wedbush
Monte Rosa Therapeutics price target raised to $37 from $26 at Wedbush
Target:$37.00
+52.2%from $24.31
Dec 17, 2025Jefferies
Monte Rosa Therapeutics (GLUE) PT Raised to $22 at Jefferies
Target:$22.00
+17.9%from $18.66
Dec 16, 2025Wells Fargo
Monte Rosa Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Target:$22.00
+33.7%from $16.45

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance